Notice2024-21859
National Institute on Drug Abuse; Notice of Closed Meetings
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
September 25, 2024
Issuing agencies
Health and Human Services DepartmentNational Institutes of Health
Full Text
<html>
<head>
<title>Federal Register, Volume 89 Issue 186 (Wednesday, September 25, 2024)</title>
</head>
<body><pre>
[Federal Register Volume 89, Number 186 (Wednesday, September 25, 2024)]
[Notices]
[Page 78321]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2024-21859]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse; Notice of Closed Meetings
Pursuant to section 1009 of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and/or contract proposals
and the discussions could disclose confidential trade secrets or
commercial property such as patentable material, and personal
information concerning individuals associated with the grant
applications and/or contract proposals, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; Device Based Treatments for Substance Use Disorders.
Date: October 30, 2024.
Time: 10:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institute of Health, National Institute on Drug
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual
Meeting).
Contact Person: Preethy Nayar, Ph.D., Scientific Review Officer,
Scientific Review Branch, Office of Extramural Policy, National
Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue, MSC
6021, Bethesda, MD 20892, (301) 443-4577, <a href="/cdn-cgi/l/email-protection#2c424d554d5e5c1e6c4f5f5e02424544024b435a"><span class="__cf_email__" data-cfemail="28464951495a581a684b5b5a06464140064f475e">[email protected]</span></a>.
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; Analytical Service Center for Medications
Development Program.
Date: October 30, 2024.
Time: 12:00 p.m. to 2:00 p.m.
Agenda: To review and evaluate contract proposals.
Place: National Institute of Health, National Institute on Drug
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual
Meeting).
Contact Person: Trinh T. Tran, Ph.D., Scientific Review Officer,
Scientific Review Branch, Office of Extramural Policy, National
Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue, MSC
6021, Bethesda, MD 20892, (301) 827-5843, <a href="/cdn-cgi/l/email-protection#a6d2d4cfc8ce88d2d4c7c8e6c8cfce88c1c9d0"><span class="__cf_email__" data-cfemail="0276706b6c6a2c7670636c426c6b6a2c656d74">[email protected]</span></a>.
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; Developing Regulated Therapeutic and Diagnostic
Solutions for Patients Affected by Opioid and/or Stimulants Use
Disorders.
Date: November 7-8, 2024.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institute of Health, National Institute on Drug
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual
Meeting).
Contact Person: Sudhirkumar U. Yanpallewar, M.D., Scientific
Review Officer, Scientific Review Branch, Office of Extramural
Policy, National Institute on Drug Abuse, NIH, 301 North Stonestreet
Avenue, MSC 6021, Bethesda, MD 20892, (301) 443-4577,
<a href="/cdn-cgi/l/email-protection#5b282e3f333229302e363a2975223a352b3a37373e2c3a291b353233753c342d"><span class="__cf_email__" data-cfemail="e99a9c8d81809b829c84889bc7908887998885858c9e889ba9878081c78e869f">[email protected]</span></a>.
Name of Committee: National Institute on Drug Abuse Initial
Review Group; Medication Development Research Study Section.
Date: November 13, 2024.
Time: 9:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institute of Health, National Institute on Drug
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual
Meeting).
Contact Person: Preethy Nayar, Ph.D., Scientific Review Officer,
Scientific Review Branch, Office of Extramural Policy, National
Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue, MSC
6021, Bethesda, MD 20892, 301-443-4577, <a href="/cdn-cgi/l/email-protection#1e707f677f6c6e2c5e7d6d6c3070777630797168"><span class="__cf_email__" data-cfemail="0e606f776f7c7e3c4e6d7d7c2060676620696178">[email protected]</span></a>.
(Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug
Abuse Scientist Development Award for Clinicians, Scientist
Development Awards, and Research Scientist Awards; 93.278, Drug
Abuse National Research Service Awards for Research Training;
93.279, Drug Abuse and Addiction Research Programs, National
Institutes of Health, HHS)
Dated: September 19, 2024.
Lauren A. Fleck,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2024-21859 Filed 9-24-24; 8:45 am]
BILLING CODE 4140-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on September 25, 2024.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.